Does Vitamin D improve markers of vascular health in stroke patients?

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-001324-13-GB

Enrollment

Registered

2007-05-16

Start date

2007-05-23

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke (Ischaemic and haemorrhagic) MedDRA version: 9.1 Level: LLT Classification code 10023027 Term: Ischaemic stroke NOS MedDRA version: 9.1 Level: LLT Classification code 10048863 Term: Hemorrhagic stroke

Interventions

Trade Name: Ergocalciferol Product Name: Ergocalciferol tablets BP 0.25mg Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinical diagnosis of completed stroke (ischaemic or haemorrhagic) Serum 25 hydroxy Vitamin D level of =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Hyper- or hypocalcaemia (calcium 2.60 mmol/L Metastatic malignancy LFTs > 3x upper limit of normal Estimated GFR <40ml/min Previous clinical diagnosis of osteomalacia Taking vitamin D preparations Unable to give written informed consent Unable to swallow tablets orally Atrial fibrillation

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine whether a single dose of 100,000 units ergocalciferol can reduce blood pressure in patients who have previously suffered a stroke;Secondary Objective: To determine whether a single dose of 100,000 units ergocalciferol can improve markers of vascular health (including endothelial function, B type natriuretic peptide, heart rate variability) in patients who have previously suffered a stroke;Primary end point(s): Change in blood pressure between active and placebo group	—

Measure

Time frame

Main Objective: To determine whether a single dose of 100,000 units ergocalciferol can reduce blood pressure in patients who have previously suffered a stroke;Secondary Objective: To determine whether a single dose of 100,000 units ergocalciferol can improve markers of vascular health (including endothelial function, B type natriuretic peptide, heart rate variability) in patients who have previously suffered a stroke;Primary end point(s): Change in blood pressure between active and placebo group

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026